ArticleBMC immunology2021
Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist.
Article in BMC immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- AI-guided CRISPR screening reveals therapeutic targets in psoriasis.Nature communications · 2026Article
- Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis.EMBO molecular medicine · 2026Article
- Effects of Overload on Imiquimod-Induced Psoriasis Model Mice: A Basic Experimental Study.Health science reports · 2026Article
- Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis.The Journal of investigative dermatology · 2026Review
- Polyphyllins ameliorate imiquimod-induced psoriatic skin barrier disruption and lesions in mice by inhibiting inflammatory infiltration with accelerated recovery effects.Frontiers in immunology · 2026Article
- Question-Driven Selection of Psoriasis Animal Models: A Structured Narrative Review of 48 Model Records.Journal of inflammation research · 2026Review
- Induction of high numbers of TBMC immunology · 2025Article
- TRPV1 Blocker, Peptide HCRG21 from Sea AnemoneInternational journal of molecular sciences · 2025Article
- Natural plant-derived nanovesicles for effective psoriasis therapy via dual modulation of IL-17 and NRF2 pathway.iScience · 2025Article
- A tryptophol-containing emulgel ameliorates imiquimod-induced mice psoriasis.Scientific reports · 2025Article
- Article
- Conjugation of Gold Nanoparticles to the Anti-IL17A Aptamer Improves Anti-Inflammatory Effects of the Aptamer in the Experimental Imiquimod-Induced Psoriasis.International journal of inflammation · 2025Article
- Comprehensive analysis of pyroptosis-related genes in psoriasis and targeted gene editing of CASP1 and CASP5 using lipid nanoparticles to alleviate skin inflammation.Frontiers in bioengineering and biotechnology · 2025Article
- Microneedles with Implantable Tip-Accumulated Therapeutics for the Long-Term Management of Psoriasis.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Tanshinol ameliorates imiquimod-induced psoriasis by inhibiting M1 macrophage polarization through suppression of the notch signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.International journal of molecular sciences · 2024Review
- Article
- Evaluation ofMediators of inflammation · 2024Article
- Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity in Mice: A New Approach for Improved Topical Drug Delivery.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-17A (IL17A) is a proinflammatory cytokine critically involved in autoimmune diseases, and monoclonal antibodies of IL17A have been approved for clinical treatment of psoriasis. However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists. Imiquimod (IMQ)-induced psoriasis model is widely used in fundamental research, but it's not able to accurately show anti-psoriatic effect of IL17A antagonists with conventional modelling condition.
resultsOn female C57BL/6 mice, with optimization on the usage of IMQ, positive control reagent and anti-mIL17A antibody, a 7-day model with proper testing window, acceptable disease severity as well as high repeatability was developed, and the efficacy of IL17A antagonist can be objectively evaluated by several qualitative and quantitative indices. Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation. This finding on the kinetical change of IL17A signaling will manifest the pharmacokinetics-pharmacodynamics investigation of IL17A antagonists.
conclusionsOur work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A's role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.